
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Supplements and Featured Publications
This AJMC® brochure focuses on managed care considerations in the treatment of Hemophilia B and Hemophilia A.





